Nasdaq

OKYO Pharma Files Application for Fast Track Designation for Urcosimod in Treatment of Neuropathic Corneal Pain

OKYO Pharma Limited has filed for Fast Track designation with the U.S. FDA for its drug urcosimod, aimed at treating neuropathic corneal pain, a painful eye condition currently lacking an FDA-approved ...
Monthly Prescribing Reference

OKYO Pharma Seeks Fast Track for Urcosimod in Neuropathic Corneal Pain

Urcosimod is currently being evaluated in a phase 2 trial evaluating it's efficacy and safety in adults with neuropathic corneal pain. OKYO Pharma has filed a Fast Track designation application with ...
UPI

China to fast-track applications for rare-earth minerals to U.S., EU

June 7 (UPI) --China has agreed to fast-track approvals for the shipment of rare earth minerals to the United States and some European Union nations. U.S. President Donald Trump and Chinese leader Xi ...
The Manila Times

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibrom…

Fast Track designation is one of the FDA’s expedited programs meant to facilitate development and expedite review of new ...